- Home
- / Radiopharm Theranostics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Radiopharm Theranostics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-04
Revenue
$3.6 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 15, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| AUD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 292.0K | 299.0K | 3.6M | ||
| Cost of goods sold | 3.6M | ||||
| Gross profit | 9.0K | 6.2M | 2.0M | 9.4M | |
| Gross profit margin, % | 2126.4% | 655.2% | 259.0% | ||
| Operating expense total | 484.0K | 16.9M | 33.6M | 43.0M | 41.5M |
| Depreciation and amortization | 3.0M | 6.4M | 4.6M | 2.6M | |
| EBITDA | (484.0K) | (16.9M) | (27.4M) | (41.1M) | (32.0M) |
| EBITDA margin, % | -9388.0% | -13732.8% | -882.1% | ||
| EBIT | (485.0K) | (19.9M) | (34.4M) | (45.7M) | (39.2M) |
| EBIT margin, % | -11772.3% | -15273.2% | -1079.0% | ||
| Interest income | 145.0K | 50.0K | 888.0K | ||
| Interest expense | 9.4M | 86.0K | 643.0K | 65.0K | |
| Pre tax profit | (485.0K) | (30.4M) | (34.6M) | (47.9M) | (38.2M) |
| Income tax expense | 44.0K | 38.0K | 96.0K | 103.0K | |
| Net Income | (485.0K) | (30.4M) | (34.6M) | (47.9M) | (38.3M) |